In May 2017, VolitionRx presented the final data from its 8,000-person clinical validation study of the Nu.Q™ Colorectal Cancer Screening Triage Test. Patients screened with this product would have required 24.5% fewer colonoscopies. The first potential market will be Denmark with feedback expected in about September 2017.
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.